항체약물접합체(ADC) 시장 : 제품 유형별, 링커 유형별, 용도별, 유통 채널별, 지역별

The global antibody drug conjugates market is estimated to be valued at US$ 5.38 billion in 2023 and is expected to reach US$ 13.65 billion by 2030, exhibiting a CAGR of 14.2% during the forecast period (2023-2030).

Global Antibody Drug Conjugates Market Share (%), By Product Type, 2023

Antibody Drug Conjugate (ADC) is typically made up of a monoclonal antibody (mAb) covalently attached to a cytotoxic drug via a chemical linker. It combines the advantages of highly specific targeting ability and a highly potent killing effect to achieve accurate and efficient elimination of cancer cells, making it one of the hotspots for anticancer drug research and development. Since the approval of the first ADC, Padcev (gemtuzumab ozogamicin) in 2000 by the U.S. Food and Drug Administration (FDA), till now 14 ADCs have been approved for market use worldwide. Furthermore, over 100 ADC candidates are currently being studied in clinical stages. Antibody-drug conjugates attach highly potent cytotoxic anticancer agents to monoclonal antibodies via biodegradable, stable linkers and discriminate between cancer and normal tissue. These linkers are either cleavable or non-cleavable. Linker technology advancements are required to attach monoclonal antibodies to cytotoxic anticancer agents, allowing control over drug pharmacokinetics and significantly improving cytotoxic agent delivery to cancer cells. The specific binding of the targeting antibody-drug conjugate to the specific tumor antigen and the internalization of the antigen-antibody complex to ensure focused delivery of the conjugated cytotoxic agent inside tumor cells are critical to the efficacy of antibody-targeted chemotherapy.

Market Dynamics

Approvals of novel ADC candidates for the treatment of cancer are anticipated to support the market growth over the forecasted period. For instance, on February 3, 2023, Gilead Sciences, Inc., a pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) granted approval for Trodelvy (sacituzumab govitecan-hziy) to be used in treating adult patients afflicted with inoperable locally advanced or metastatic breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH-). These patients should have previously undergone endocrine-based therapy and received a minimum of two additional systemic therapies in the metastatic phase.

Key features of the study:

• This report provides an in-depth analysis of the global antibody drug conjugates market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global antibody drug conjugates market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global antibody drug conjugates market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibody drug conjugates market

Detailed Segmentation:

• By Product Type:
  • Adcetris
  • Kadcyla
  • Enhertu
  • Trodelvy
  • Padcev
  • Others (Blenrep, Tivdak, Zynlota, Elahere, etc.)
• By Linker Type:
  • Non-cleavable Linker
  • Cleavable Linker
• By Application:
  • Blood Cancer
  • Breast Cancer
  • Ovary Cancer
  • Lung Cancer
  • Skin Cancer
  • Brain Tumor
  • Others (Renal Caner, Urothelial & Bladder Cancer, etc.)
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Novasep
  • ADC Therapeutics SA
  • Alentis Therapeutics AG
  • F. Hoffmann-La Roche
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Biosion USA, Inc.
  • Astellas Pharma Inc.
  • Duality Biologics (Suzhou) Co. Ltd.
  • BioNTech SE
  • LaNova Medicines Ltd.
  • Bliss Biopharmaceutical
  • Eisai Co., Ltd.
  • ProfoundBio
  • Pfizer, Inc.
  • ImmunoGen Inc.
  • Mersana Therapeutics Inc.
  • Sorrento Therapeutics Inc.
  • Oxford BioTherapeutics Ltd
  • Takeda Pharmaceutical Company Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Linker Type
  • Market Snippet, By Application
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Antibody Drug Conjugates Market - COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Antibody Drug Conjugates Market, By Product Type, 2018 - 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Adcetris
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Kadcyla
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Besponsa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Lumoxiti
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Mylotarg
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Others (Polivy, Lumoxiti, Zynlonta, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends

6. Global Antibody Drug Conjugates Market, By Linker Type, 2018 - 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Non-Cleavable Linker
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends
• Cleavable Linker
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Segment Trends

7. Global Antibody Drug Conjugates Market, By Application, 2018 - 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Blood Cancer
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Breast Cancer
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Ovary Cancer
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Lung Cancer
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Skin Cancer
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Brain Tumor
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Others
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends

8. Global Antibody Drug Conjugates Market, By Distribution Channel , 2018 - 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
• E-commerce
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

9. Global Antibody Drug Conjugates Market, By Region, 2018 - 2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Company Profiles
  • AstraZeneca PLC
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Daiichi Sankyo Company, Limited
  • Novasep
  • ADC Therapeutics SA
  • Alentis Therapeutics AG
  • F. Hoffmann-La Roche
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Biosion USA, Inc.
  • Astellas Pharma Inc.
  • Duality Biologics (Suzhou) Co. Ltd.
  • BioNTech SE
  • LaNova Medicines Ltd.
  • Bliss Biopharmaceutical
  • Eisai Co., Ltd.
  • ProfoundBio
  • Pfizer, Inc.
  • ImmunoGen Inc.
  • Mersana Therapeutics Inc.
  • Sorrento Therapeutics Inc.
  • Oxford BioTherapeutics Ltd
  • Takeda Pharmaceutical Company Ltd

11. Section

• References
• Research Methodology
• About us and Sales Contact